Gland Pharma Q4 Results: Pharma company Gland Pharma on Tuesday, May 20, posted a weak set of numbers for the fourth quarter of the financial year 2024-25 (Q4 FY25), recording a single-digit fall in the consolidated revenue and profit after tax (PAT).
Gland Pharma’s PAT came in at ₹187 crore for the quarter under review, as against ₹192 crore in the year-ago quarter, recording a 3% decline on a year-on-year basis.
